000			01947 a2200565 4500
005			20250518030613.0
264		0	_c20200902
008			202009s 0 0 eng d
022			_a1179-1926
024	7		_a10.1007/s40262-019-00754-4 _2doi
040			_aNLM _beng _cNLM
100	1		_aRolfo, Christian
245	0	0	_aPharmacokinetics and Safety of Olaparib in Patients with Advanced Solid Tumours and Renal Impairment. _h[electronic resource]
260			_bClinical pharmacokinetics _c09 2019
300			_a1165-1174 p. _bdigital
500			_aPublication Type: Clinical Trial, Phase II; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
650	0	4	_aAdministration, Oral
650	0	4	_aAdult
650	0	4	_aAged
650	0	4	_aFemale
650	0	4	_aHumans
650	0	4	_aKidney _xphysiopathology
650	0	4	_aMale
650	0	4	_aMetabolic Clearance Rate _xdrug effects
650	0	4	_aMiddle Aged
650	0	4	_aNeoplasms _xcomplications
650	0	4	_aNo-Observed-Adverse-Effect Level
650	0	4	_aPhthalazines _xadministration & dosage
650	0	4	_aPiperazines _xadministration & dosage
650	0	4	_aPoly(ADP-ribose) Polymerase Inhibitors _xadministration & dosage
650	0	4	_aRenal Insufficiency _xetiology
650	0	4	_aSafety
700	1		_ade Vos-Geelen, Judith
700	1		_aIsambert, Nicolas
700	1		_aMolife, L Rhoda
700	1		_aSchellens, Jan H M
700	1		_aDe Grève, Jacques
700	1		_aDirix, Luc
700	1		_aGrundtvig-Sørensen, Peter
700	1		_aJerusalem, Guy
700	1		_aLeunen, Karin
700	1		_aMau-Sørensen, Morten
700	1		_aPlummer, Ruth
700	1		_aLearoyd, Maria
700	1		_aBannister, Wendy
700	1		_aFielding, Anitra
700	1		_aRavaud, Alain
773	0		_tClinical pharmacokinetics _gvol. 58 _gno. 9 _gp. 1165-1174
856	4	0	_uhttps://doi.org/10.1007/s40262-019-00754-4 _zAvailable from publisher's website
999			_c29483464 _d29483464